StephanieNovielloMD

Physician

Dr. Noviello is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

PubMed

930 citations
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.
John G. McHutchison, Eric Lawitz, Mitchell L. Shiffman, Andrew J. Muir, Greg Galler
The New England Journal of Medicine. 2009-12-10
6 citations
Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison
Elyse Swallow, Jinlin Song, Yong Yuan, A. Kalsekar, Caroline Kelley
Journal of Comparative Effectiveness Research. 2016-03-01
550 citations
Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus
Alexander J. Thompson, Andrew J. Muir, Mark S. Sulkowski, Dongliang Ge, Jacques Fellay
Gastroenterology. 2010-07-01

Journal Articles

The Lancet Child & Adolescent Health
Arun Sanyal, Stephen A Harrison, Edgar D Charles, Stephanie Noviello, Manal F Abdelmalek, Eric J Lawitz, Rohit Loomba, The Lancet
Daclatasvir and Sofosbuvir with Ribavirin for 24 Weeks in Chronic Hepatitis C Genotype-3-Infected Patients with Cirrhosis: A Phase III Study (ALLY-3C)
Mitchell L Shiffman, Stephanie Noviello, Gregory D Huhn, Antiviral Therapy

Motif Bio Reports Fiscal Year 2018 ResultsApril 26th, 2019
Is Selling Motif Bio Plc (MTFB) Here a Winning Strategy?April 15th, 2019
Motif Bio Plc (MTFB) EPS Estimated at $-0.45; Silicom Ltd – Ordinary Shares (SILC) SI Decreased by 44.28%April 3rd, 2019
Join now to see all